GATC Biotech’s Sanger sequencing services receive Platinum Seal of Quality from SelectScience

Press Releases   •   Jun 29, 2017 10:00 BST

GATC Biotech receives the platinum SelectScience® Seal of Quality for its two Sanger sequencing services, SUPREMERUN and LIGHTRUN for the year 2017.

Media no image

GATC to be part of Eurofins Group

Press Releases   •   Jun 02, 2017 07:30 BST

Constance, Germany, June 2nd, 2017: GATC, one of the leading sequencing provider will be a part of the Eurofins Group as of July 2017 to create the leading company in the worldwide sequencing market.

Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, announces that it has signed an agreement to acquire GATC Biotech AG (“GATC”), one of Europe´s specialists in DNA sequencing. The transaction is expected to close in July, subject to the fulfilment of customary closing conditions.

Founded in 1990, GATC has achieved a strong recognition for DNA and RNA sequencing, as well as bioinformatics in Europe. The company employs 140 staff across 2 sites, and serves over 10,000 institutional and academic customers, generating annual revenues of about EUR 20m. As one of the larger players in Custom and Next Generation Sequencing, GATC has built a reputation for innovative, internally-developed applications, as well as industry-leading turn-around time (TAT). The acquisition should therefore further reinforce Eurofins' footprint in DNA sequencing, and strengthen the Group's technological platform supporting its genetic testing innovations.

Comment from Peter Pohl, CEO and Co-Founder GATC: “We are excited to be joining the Eurofins family of laboratories and look forward to the next phase of our development within the Group. We are confident that with access to Eurofins’ global network and technical competencies, we should be able to expand our analytical portfolio and services to benefit all our existing and future clients.”

Comment from Dr. Gilles Martin, Eurofins CEO: “We look forward to providing GATC access to the complete capabilities of the Eurofins Group. This transaction is a demonstration of Eurofins' commitment to genomics services. We believe that advances in gene sequencing will continue to drive innovations not only in clinical diagnostics, but in the broader bioanalytical testing market as well."

For the purchase price secrecy was agreed.

About GATC Biotech:

GATC Biotech, a family owned business since 1990, is Europe’s leading sequencing services provider with more than 10,000 customers from academia, industry and healthcare worldwide. As a renowned brand, GATC Biotech offers all leading sequencing technologies in its own laboratories. The company’s proprietary workflows deliver ready-for-diagnostics results backed by ISO 17025 accreditation. From Sanger to next-generation sequencing, GATC Biotech offers unmatched flexibility for any kind of genomics such as transcriptome, epigenome, exome or whole genome analysis. Please visit www.gatc-biotech.com for more information on genomic innovation – Made in Germany.

About Eurofins:

Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 28,000 staff in 310 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).www.eurofins.com

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.

GATC, one of the leading sequencing provider will be a part of the Eurofins Group as of July 2017.

Read more »

GATC Biotech launches most comprehensive cancer panel for profiling of any tumour type

Press Releases   •   May 23, 2017 09:00 BST

GATC Biotech launches cancer gene panel of about 600 genes for liquid biopsy and tissue samples.

Media no image

Alliance for “Next Generation Sequencing”: GATC Biotech AG and the Konstanz Research School Chemical Biology sign co-operation agreement

Press Releases   •   Apr 06, 2017 10:52 BST

Constance, Germany, 31 March 2017: DNA sequencing, in which the sequence of the bases or nucleotides which make up genetic material is determined, is one of the most important processes for genome analysis. Progress in “Next Generation” processes for DNA sequencing hold high potential for fundamental research and medical diagnosis. The Konstanz Research School Chemical Biologyof the University of Constance and GATC Biotech, a leading sequencing service provider, have now signed an agreement for a close scientific and cost-efficient cooperation in the field of ”Next Generation Sequencing” (NGS). The aim of this agreement is to establish an ”Alliance for Sequence and TRanscript Analysis” (ASTRA) in order to further develop and expand modern sequencing processes. The co-operation was establishedduring a mutual workshop for both partners, mediated by the BioLAGO life science network.

The ASTRA alliance combines the excellent infrastructure of GATC Biotech with University of Constance research projects whose main focus is on chemical biology.

“With the current agreement, we create mutual benefits for both partners”, explained Prof. Dr. Andreas Marx, spokespersonfor the Konstanz Research School Chemical Biology. “Our research projects benefit from the cost-efficient sequencing at GATC, while at GATC, novel developments are realised thanks to our research projects.”

With the help of the new co-operation, the Konstanz Research School Chemical Biologyhas the possibility to deploy the newest form of genome analysis in its research projects and to make use of GATC's state-of-the-art infrastructure. GATC supports the researchers with its know-how through affordable and high-quality sequencing and offers consultation in project design.

“We want to support the university in its research work with our efficient laboratories and our experience indeciphering genetic material,”, said Dr. Marcus Benz, Member of the Executive Board of GATC Biotech.

The new alliance should not only expand and exhilarate effective research in chemical biology, but also transform the technological advantage into scientific and financial success. GATC is already involved in many partially publicly subsidised projects with numerous research facilities and can contribute the required know-how to this newly founded collaboration.

Chemical biology and the field of life sciences are one of four profile sectors of the University of Constance. The Konstanz Research School Chemical Biology, which is jointly coordinated by the Constance departments Biology, Chemistry, as well as Computer Science and Information Science, was successful in both phases of the Excellence Initiative of the federal government and the federal states. It was approved for two funding phases from 2007 to 2017 and is currently funded until 31 December 2018. To-date, more than 220 PhD theses have been launched and 115 of them have already been completed successfully.

Facts overview

  • Cooperation goal: establishing an “Alliance for Sequence and TRanscript Analysis“ (ASTRA) for further developing modern sequencing processes.
  • Agreement: use of the infrastructure of GATC Biotech for research projects of the Graduiertenschule Chemische Biologie

GATC Biotech AG, with its headquarters in Constance, Germany, is Europe's leading provider in the field of genotype analysis. Since 1990, the power of innovation and quality have formed the trademark for DNA and RNA sequencing, as well as bioinformatics at the highest level. The family business is already supporting more than 10,000 customers in the fields of industry, healthcare and academic research in 40 countries in reaching their goals. Currently, the entrepreneurial energy is focused on a completely new approach for the field of personalised healthcare. As a medium-sized company, GATC Biotech can demonstrate considerable track records of publicly subsidies projects. Together with various European partners, it regularly conducts research projects for publicly subsidised subjects. Learn more on: www.gatc-biotech.com.

The Konstanz Research School Chemical Biology of the University of Constance and GATC Biotech, a leading sequencing service provider, have now signed an agreement for a close scientific and cost-efficient cooperation in the field of ”Next Generation Sequencing” (NGS).

Read more »

GATC celebrates the 2nd Million Watchbox

Press Releases   •   Feb 15, 2017 09:30 GMT

German sequencing solutions provider GATC Biotech AG delivered the 2nd million watchbox and celebrated the occasion together with the lucky customer


New exome product facilitates cost-efficient variant detection in hereditary diseases

Press Releases   •   Dec 05, 2016 07:00 GMT

The new INVIEW HUMAN EXOME EXPLORE applies streamlined workflows for cost-effective exome analysis with uncompromised data quality.


GATC Biotech showcases world’s only service lines for direct comparison of liquid and tissue biopsy samples at the MEDICA

Press Releases   •   Nov 14, 2016 07:15 GMT

GATC Biotech presents exclusive product portfolio for simultaneous analysis of tumour tissue and liquid biopsy samples at this year's MEDICA.


Find all metagenomes: GATC Biotech introduces new products for taxonomic and functional profiling

Press Releases   •   Nov 03, 2016 09:35 GMT

GATC Biotech announced today the release of ​INVIEW METAGENOME, a new product line for metagenome analysis. The unique new service is based on sequencing and analysing the DNA of all organisms in a sample, independent of their taxonomic origin.



Press Releases   •   Sep 21, 2016 09:00 BST

GATC Biotech and Bluebee team up for superior whole genome data analysis


Precision monitoring of more than 15 common cancers now feasible with GATCLIQUID ONCOTARGET

Press Releases   •   Jul 27, 2016 07:00 BST

GATC Biotech expands target list of liquid biopsy-based service for detection of most important mutations in more than 15 frequently diagnosed cancers

Images & Videos 5 images

About GATC Biotech

DNA Sequencing and Bioinformatics

GATC Biotech, a family-owned business, is one of the world´s leading service provider of DNA and RNA sequencing. For over two decades, the company has offered sequencing and bioinformatics solutions from single samples up to large scale projects. During this time, GATC Biotech has developed to a renowned brand, not only mastering a broad range of technologies and related downstream data analysis, but also processing millions of customer samples in professional quality and ready for diagnostic purposes.

The company offers true multiplatform sequencing using all leading sequencing technologies in its own labs. Its headquarter in Constance, Germany houses its ISO 17025 certified 'Genome and Diagnostic Centre' with a focus on next and third generation sequencing. The European Custom Sequencing Centre located in Cologne, Germany focuses on GATC Biotech’s Sanger sequencing service. This advantageous location ensures rapid and efficient sample logistics. All laboratories have highly integrated and fully automated processing pipelines, ensuring full compliance with latest state-of-the-art quality standards.

Please visit www.gatc-biotech.com for more information


  • GATC Biotech
  • Jakob-Stadler-Platz 7
  • 78467 Konstanz
  • Germany